Gerald S. Weinstein, MD
Gerald S. Weinstein, MD
Biography

News for Healthier Living

Mayo Clinic Uses Investigational Targeted Radiopharmaceutical Theranostic for Hepatocellular Carcinoma in First-in-Human Clinical Trial

Mayo Clinic recently became the first institution to administer an investigational radioactive medicine to a patient with hepatocellular carcinoma (HCC), the most common type of liver cancer. The investigational medicine is a targeted radiopharmaceutical theranostic (RPT) that is designed to target a novel protein called glypican-3 (GPC3). The RPT was administered to the patient as part of a first-in-human clinical trial for the targeted therapy. This investigational RPT includes both a diagnostic imaging agent, intended to identify the cancer cells, and a therapeutic agent, intended to target and kill cancer cells.

October 6, 2025


October 16 2025

October 15 2025

October 14 2025

October 13 2025

October 12 2025

October 11 2025

October 10 2025

October 9 2025

October 8 2025

October 7 2025

October 6 2025

October 5 2025

October 4 2025

October 3 2025

October 2 2025